Kailera trades 29% below April IPO with $1.17 billion in cash
The Hengrui-partnered obesity developer owes up to $5.725 billion in commercial milestones, complicating acquirer math ahead of 2028 Phase 3 data.
TR
By Tom Reyes · Markets Editor
Aug 18 03:00 ETSource: 24/7 Wall St.
The wire
- 01Kailera Therapeutics closed at $18.51 for a $2.40 billion market cap, down 28.8% since April trading began, holding $1.17 billion in cash, a $111.31 million Q2 net loss and runway into mid-2028.
- 02Its GLP-1/GIP dual agonist ribupatide anchors the 4,700-participant global Phase 3 KaiNETIC program, with a fully enrolled 264-patient US Phase 2b high-dose trial reading out mid-2027.
- 03Under the Hengrui license Kailera has paid $100 million upfront plus a $10 million technology transfer payment and owes up to $200 million in clinical and regulatory milestones; the piece is takeover speculation, not a reported deal.
From the source
Read at 247wallst.comKailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.